Please provide your email address to receive an email when new articles are posted on . PARIS — In patients with acute coronary syndromes, with or without ST-segment elevation, the rate of death, MI ...

For patients with ACS in whom an invasive strategy is planned, diabetes status appears to affect the relative safety and efficacy of ticagrelor versus prasugrel, a prespecified analysis of the ...

For STEMI patients undergoing primary PCI, there are no significant differences in the risks of death, MI, or stroke between those treated with prasugrel and those who received ticagrelor, nor are ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. New research from the ISAR-REACT 5 trial indicated that ...

PARIS — Among patients hospitalized for acute coronary syndrome (ACS) and scheduled to have invasive coronary angiography, those who received an antiplatelet treatment strategy with prasugrel (Effient ...

PARIS -- In a large head-to-head trial of two P2Y12 Inhibitors, prasugrel (Effient) significantly lowered rates of ischemic events versus ticagrelor (Brilinta) for patients with acute coronary ...

Poor kidney function predicts worse outcomes in acute coronary syndrome (ACS) but not less benefit of prasugrel (Effient) over ticagrelor (Brilinta) in dual antiplatelet therapy for those headed to ...